J.P. Morgan analyst Cory Kasimov maintained a Hold rating on BioNTech SE (NASDAQ:BNTX) on Thursday, setting a price target of $133, which is approximately 41.17% below the present share price of $226.09.
Kasimov expects BioNTech SE to post earnings per share (EPS) of $4.64 for the second quarter of 2021.
The current consensus among 9 TipRanks analysts is for a Hold rating of shares in BioNTech SE, with an average price target of $182.
The analysts price targets range from a high of $240 to a low of $133.
In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $2.05 billion and a net profit of $1.62 billion. The company's market cap is $54.61 billion.
According to TipRanks.com, J.P. Morgan analyst Cory Kasimov is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 19.2% and a 55.11% success rate.
BioNTech SE is a Germany-based biotechnology company that develops and manufactures immunotherapies for cancer, infectious diseases, allergies and autoimmune disorders.